Funding Agency Stop Work Orders: Sample IRB Guidelines for Investigators. View Now
Skip to main content

How to Read a Reg Roundup: A Short Guide to Rules, Notices, Guidance, and Dates

Posted on by

This guide is general information, not legal advice. Agency practices change, so confirm current requirements before relying on any detail below.

Our Reg Roundup covers a lot of ground in a short space. In a single edition you might see a final rule, a proposed rule that has not been published yet, a draft guidance, a request for public input, and a routine paperwork notice. They all look like “news from the feds,” but they can mean very different things for your institution or organization.

This guide gives you a quick way to evaluate any item in the roundup. For each item, ask five questions:

  • What kind of document is it?
  • Where is it in the process?
  • How much should I trust the date?
  • Does it bind my institution?
  • What, if anything, should I do about it?

Question 1: What kind of document is it?

How a federal announcement is categorized matters more than its headline. Here are the types you will see most often.

What you seeWhat it isDoes it bind you?Example from the roundup
Final ruleA regulation the agency has finished. Generally takes effect at least 30 days after publication.Yes, once effectiveFDA’s rule replacing “animal test” language with “nonclinical test”
Proposed rule (NPRM)A draft regulation published for public commentNo, it is a proposalFDA’s planned overhaul of sponsor and investigator duties under Part 312 (when published)
Unified Agenda entryThe agency’s forecast of rules it is working onNo, it is a forecastThe Common Rule revision (RIN 0937-AA16)
Request for information (RFI), discussion paper, or draft policyAn agency asking for input on a policy it has not finalizedNoFDA’s generative AI device discussion paper; NIH’s draft biosafety policy
Guidance or FAQThe agency’s recommended approach to meeting a requirementGenerally no, unless it repeats a regulatory requirementOHRP’s August 2026 FAQ on basic experimental studies and consent posting
Information collection noticeA paperwork notice under the Paperwork Reduction Act (PRA)about a form, survey, or recordkeeping requirementNot by itselfFDA’s renewal notice for control number 0910-0130

Guidance. Guidance is the category that most often trips up research compliance teams. The Administrative Procedure Act (APA) lets agencies issue interpretive rules and policy statements, which together are known as guidance, without going through notice and comment, and these documents generally do not carry the force of law (CRS LSB10591). OHRP guidance says so directly: “must” means something is required under 45 CFR part 46, “should” means it is recommended, and an institution may use an alternative approach if it satisfies the regulations (OHRP guidance). That does not make guidance unimportant. It shows you what the agency considers a compliant approach, and it is often the best predictor of how an auditor or inspector will think. It does mean you have more flexibility than many people assume; if your institution differs from published guidance, we recommend that the reasoning be clearly documented.

Information collection notices. These are the most common and least exciting items in any roundup, and the easiest to misread. A notice that an agency wants to renew or change a form is not a change to a regulation. Under the PRA, an agency generally must publish a notice with a 60-day comment period, then submit the collection to the Office of Management and Budget (OMB) and publish a second notice opening a 30-day comment period (Reginfo.gov FAQ). OMB approvals last up to three years, and an agency must seek renewal at least 60 days before the control number expires (44 U.S.C. 3507). So a notice that arrives close to an expiration date usually signals routine renewal. A notice that arrives years ahead of schedule, as we noted for the Certificate of Confidentiality system, suggests the agency wants to change something.

Question 2: Where is it in the process?

For rules, think of a ladder. The agency typically first lists the action in the Unified Agenda. It then drafts the proposal. If the action is “significant,” the draft goes to the Office of Information and Regulatory Affairs (OIRA) at the White House for review under Executive Order 12866. The proposal is then published in the Federal Register, the public submits comments, and the agency drafts a final rule, which may go back to OIRA before it is published (ICF Reg Map, 2020).

Most of what you see in the roundup sits on one of three rungs:

  • On the Unified Agenda, not yet at OIRA. The agency says it plans to act, but nothing has been sent for review.
  • Pending at OIRA. Reginfo.gov shows actions currently under review, but it does not show you the draft (Reginfo.gov FAQ).
  • Published. The proposal or final rule has appeared in the Federal Register.

Under Executive Order 12866, an agency generally may not publish a significant action until OIRA has completed or waived its review, or the review period has expired (Executive Order 12866, section 8). So if a significant rule has not reached OIRA, publication is generally not imminent. That is why we say in the roundup that the FDA single-IRB final rule is worth watching: once it shows up as received at OIRA, the timeline becomes much easier to estimate.

Not everything at OIRA is a rule. Some items on the “pending White House review” list in our roundup, such as FDA’s planned guidance on clinical trial enrollment action plans, are guidance. Whether guidance goes through White House review has depended on executive orders that have changed across administrations (CRS LSB10591).

Question 3: How much should I trust the date?

Less than you would like. A date next to “NPRM” or “Final Rule” in the Unified Agenda is the agency’s forecast, made when it prepared its entry. It is not a schedule, and it does not mean any clock has started. The agenda itself says that dates are subject to change, that agencies may act earlier or later than listed, and that the agenda creates no legal obligation to follow its schedule (2026 Unified Agenda Introduction).

A few reading tips:

  • A passed date is normal. The Common Rule entry in our roundup lists a target date that has already passed. Often, this means the work is running late, not that something has been decided.
  • Check the edition and the stage. Entries reflect the agency’s view when that edition was compiled. “Proposed Rule” and “Final Rule” mean the agency’s next step is that action. “Long-Term” means the agency does not expect action within 12 months (2026 Unified Agenda Introduction).
  • Look for a legal deadline. If a statute requires action by a certain date, that is a stronger signal of pressure on the agency than the target date, although it still does not guarantee timing.
  • Treat a month-only date as a month-only date. A date such as “12/00/2026” means the agency predicts the month and year, not the day.
  • Do not confuse comment deadlines with agenda dates. Comment deadlines, like the October 19 deadline for the FDA generative AI discussion paper, are fixed. Agenda dates are not.

Question 4: Does it bind my institution?

The general rule is that final regulations bind you once they take effect. Proposals, forecasts, discussion papers, and draft policies do not. Guidance generally does not bind your institution, except where it simply repeats a regulatory requirement. Statutes and award terms can bind you even when no regulation changes, so read the actual notice and your award terms. For example, the NIH policies related to funding might go into effect immediately, or, as with the changes to career development (or “K” awards), might go into effect in a future application or funding cycle.  Additionally, an agency can announce a change with a future effective date and later decide to implement the policy change immediately (as happened with a component of NIH’s K-award changes).

The agency’s own process offers clues. FDA, for example, generally issues a draft guidance for comment and then finalizes it, although it may implement certain guidance immediately and take comments afterward (FDA, Good Guidance Practices). OHRP follows a similar pattern for documents it labels guidance, but it may issue content-specific FAQs without a draft. A final guidance that skipped public comment still reflects the agency’s current thinking. It just has not been tested by outside input.

Question 5: What should I do about it?

After you have sorted an item, assign it to one of four buckets.

  1. Act now. The item is final or already in effect, or a deadline is near.
  2. Comment. Comment periods are one of the few ways to shape an agency’s thinking. Written comments on proposed rules go to the docket on Regulations.gov, and comments on an information collection can be submitted through reginfo.gov during the 30-day period, although comments submitted there cannot be claimed as confidential (Reginfo.gov FAQ).
  3. Prepare. The item is proposed or on the agenda, and your institution would need to change policies, training, or systems if it is finalized.
  4. Watch. The item is early, tentative, or routine. Set a reminder to check reginfo.gov, and keep an eye out for whether it appears at OIRA.

Sources

We want your feedback!

How did we do?  Let us know in the comments on LinkedIn or provide your feedback here.